Leadership

Executive Team

NuvOx Pharma, Evan C. Unger, M.D., F.A.C.R. Co-founder / Chief Executive Officer
Dr. Evan C. Unger
Co-founder, Chief Executive Officer, President

Dr. Unger has founded three biotech companies. His first company, ImaRx Pharmaceutical, developed 3 FDA approved drugs and was acquired by DuPont yielding a > 20x ROI. Dr. Unger’s second company, ImaRx Therapeutics, went public and performed clinical trials using a pioneering new technology to treat stroke. Dr. Unger co-founded NuvOx, in-licensed the core patents and obtained ownership of the regulatory documents for NuvOx’s key product. Dr. Unger is an inventor on 113 issued US patents. He is a board-certified radiologist and has an appointment as a Professor of Radiology and Biomedical Engineering at the University of Arizona.

Betty R Weaver, CPA Chief Financial Officer
Betty R Weaver, CPA
Chief Financial Officer

Ms. Weaver has over 18 years in public accounting with a regional firm in the Dallas/Fort Worth area and has principal accounting firms in Texas and Arizona. Ms. Weaver is a financial expert in providing early and expansion stage companies in Biotech and Life Sciences with planning, analysis and full CFO services. She also has over 15 years in industry with responsibility for operations, accounting, treasury, facilities, human resources and information technology. Ms. Weaver completed her BS degree in Accounting/Information Systems at University of North Texas. She holds CPA licenses in Texas and Arizona.

Rajan Ramaswami, Ph.D.
Chief Operations Officer

Dr. Ramaswami has over 15 years of experience in leading the Chemistry Manufacturing and Controls (CMC) operations for successful drug development programs at ImaRx Pharmaceuticals Corp and its successor company ImaRx Therapeutics, Inc. He has developed strategic technical programs within the CMC realm including product characterization, process development, analytical methods, formulation development, stability, and scale up processing. As a Chemistry Manufacturing and Control subject matter expert, he has reviewed product development plans, and the Module 3 section of the IND/NDA for various clients for products such as topical/dermal creams/lotions, liquid/solid dose oral formulations, nano-emulsions, and lyophilized powders for intravenous administration. Since joining NuvOx, he has assumed the primary responsibility to oversee the manufacture of the dodecafluoropentane nano-emulsions and oversee the research and development efforts of the product pipeline.

Gordon Brandt, MD Vice President of Regulatory Affairs

Gordon Brandt, MD
Vice President of Regulatory Affairs

Dr. Gordon Brandt has been working with NuvOx since 2012. Dr. Brandt’s career in drug, device and biologics development for US and international markets spans more than 30 years. He has led development teams resulting in both NDA and ANDA drug approvals in the US and in centralized marketing authorization for an ultrasound contrast agent in the EU. Dr. Brandt was most recently President and Executive Vice President Clinical/Regulatory at Nastech Pharmaceuticals, a publicly traded biotech company. Previously he led the clinical and regulatory development of EchoGen, a dodecafluoropentane ultrasound product which is the foundation of NuvOx technology. Dr. Brandt earned a medical degree from the University of California San Francisco and an engineering degree from Yale. Dr. Brandt is an author on 27 publications and five patents.

Board of Directors

NuvOx Pharma, Evan C. Unger, M.D., F.A.C.R. Co-founder / Chief Executive Officer
Dr. Evan C. Unger
Co-founder, Chief Executive Officer, President

Dr. Unger has founded three biotech companies. His first company, ImaRx Pharmaceutical, developed 3 FDA approved drugs and was acquired by DuPont yielding a > 20x ROI. Dr. Unger’s second company, ImaRx Therapeutics, went public and performed clinical trials in a pioneering new technology to treat stroke. Dr. Unger co-founded NuvOx, in-licensed the core patents and obtained ownership of the regulatory documents for NuvOx key product. Dr. Unger is inventor on 113 issued US patents. He is a board-certified radiologist and has an appointment as professor of radiology and biomedical engineering at the University of Arizona.

Jennifer L.H. Johnson, Ph.d.
Jennifer L.H. Johnson, Ph.D.
Co-founder

Dr. Johnson is a formulation chemist with an emphasis in intravenous drug delivery and extensive experience in emulsion technology. She earned her doctorate from the University of Arizona under the mentorship of the well known Pharmaceutics Professor, Dr. Samuel H. Yalkowsky. Dr. Johnson also holds an adjunct professor position in the University of Arizona College of Pharmacy and teaches a portion of a 'Solubility and Solubilization on Aqueous Media' short course offered every spring at La Paloma Resort in Tucson, Arizona. An overview of her experience in drug development includes combined microbubble and ultrasound technology for drug delivery, targeted and non-targeted micro and nano-emulsion formulation and oral and topical formulation of novel anti-cancer compounds.

Marvin Slepian, MD Director, Interventional Cardiology; Director, Tissue Engineering Lab
Marvin J Slepian, MD

Marvin J. Slepian, M.D. is Professor of Medicine (Cardiology), Director of Interventional Cardiology and Director of the Tissue Engineering Lab at the University of Arizona. Dr. Slepian completed his Internal Medicine training at NYU-Bellevue in New York where he was a Resident and Chief Resident in Medicine. He completed his Cardiology training at Johns Hopkins where he was a Clinical and Research Fellow. He completed a second fellowship in Interventional Cardiology at Cleveland Clinic. Dr. Slepian has conducted extensive research, development and pre-clinical investigation of novel cardiovascular therapeutic methods and devices, and is the holder of more than 25 issued and 41 filed patents. He is an expert in polymeric biomaterials and local drug delivery. Dr. Slepian has founded numerous medical device companies, including Focal (NASDAQ-traded, acquired by Genzyme), Endotex, Angiotrax and Hansen Medical, and has served as acting CEO and Board Member of several medical device startups. He earned his A.B. in Biochemical Sciences and Science in Human Affairs from Princeton University, and his M.D. from the University of Cincinnati College of Medicine. He has received additional post-doctoral training at MIT and Washington University.

Jonathan T. Schilling
Richard Carmona MD, MPH, FACS

Richard Carmona MD, MPH, FACS was the 17th Surgeon General of the United States and is the Distinguished Professor of Public Health at the Mel and Enid Zuckerman College of Public Health. He also holds faculty appointments as a Professor of Surgery and Pharmacy. Trained in general and vascular surgery, Dr. Carmona also completed a National Institutes of Health-sponsored fellowship in trauma, burns, and critical care. Dr. Carmona was then recruited jointly by the Tucson Medical Center and the University of Arizona to start and direct Arizona's first regional trauma care system. He went on to become the chairman of the State of Arizona Southern Regional Emergency Medical System, a professor of surgery, public health and family and community medicine at the University of Arizona, and the Pima County Sheriff's Department surgeon and deputy sheriff. He is also a Fellow of the American College of Surgeons. Dr. Carmona's interest in public health stemmed from the realization that most of his patients' illnesses and injuries were completely preventable.
In 2002 Dr. Carmona was nominated by the president and unanimously confirmed by the United States Senate to become the 17th Surgeon General of the United States. Dr. Carmona was selected because of his extensive experience in public health, clinical sciences, health care management, preparedness, and his commitment to prevention as an effective means to improve public health and reduce health care costs while improving the quality and quantity of life. As Surgeon General, Dr. Carmona focused on prevention, preparedness, health disparities, health literacy, and global health to include health diplomacy. He also issued many landmark Surgeon General Communications during his tenure, including the definitive Surgeon General's Report about the dangers of second-hand smoke.

Jonathan T. Schilling
Jonathan T. Schilling

Jonathan is retired from a 30-year career in the sale and marketing of employee benefit medical/dental plans for Blue Cross and Delta Dental. He received a BS in Information Science Management from the University of San Francisco. He is an active investor and recently invested in NuvOx and led a portion of the round totaling $1.6 Million from a group of investors. His previous investments have included Schilling Robotics (President, Tyler Schilling, Jonathan's brother), which sold in 2012 at a total valuation of several hundred million dollars. The result was an ROI of 22x for the Unit A investors. Jonathan has known Evan Unger since 1969 (high school) and now resides in San Francisco.

Michael Sember 
Michael Sember

Mike has more than 40 years of comprehensive experience working with public and private pharmaceutical, biotech and medical device companies in the U.S. and Europe. He has experience in the areas of R&D, business development, strategy and corporate finance, including involvement with over 100 licensing transactions and corporate acquisitions. Previously, Mike served in senior positions with Marion Laboratories (Marion Merrell Dow) and Elan Corporation. Mike has been CEO or COO of five public and private corporations. He has served on the boards of 14 public and private companies and also on the advisory boards of several venture capital firms. Mike received his bachelor’s degree from the University of Pittsburgh and his MBA from Rockhurst University.

Clef two-factor authentication